Publications: 2001-2007: JMG Bonfrer

  1. Missotten GS, Korse CM, Van Dehn C, Linders TC, Keunen JE, Jager MJ, Bonfrer JMG. S-100B protein and melanoma inhibitory activity protein in uveal malanoma screening. Tumor Biol 2007; 28: 63-69.
  2. Gast MC, Bonfrer JMG, van Dulken EJ, de Kock L, Rutgers EJ, Schellens JH, Beijnen JH. SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. Cancer Biomark 2006; 2(6): 235-48.
  3. Brandsma D, Voest EE, de Jager W, Bonfrer JMG, Algra A, Boogerd W, Korse T, Reijnveld JC, Verbeek MM, Rijkers G, Taphoorn MJ. CSF protein profiling using Multiplex Immuno-assay: A potential new diagnostic tool for leptomeningeal metastases. J Neurol 2006; 253(9): 1177-84. Epub 2006 Sep 22.
  4. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JMG, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24(13): 1990-6.
  5. Duffy MJ, Bonfrer JMG, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15(5): 679-91.
  6. Smit LH, Nieweg OE, Korse CM, Bonfrer JMG, Kroon BB. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol 2005; 90(2): 66-9; discussion 69-70.
  7. Smit LH, Korse CM, Bonfrer JMG. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005; 20(1): 34-42.
  8. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BG.Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004; 90(11): 2073-9.
  9. Kok M, Bonfrer JMG, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol. 2003; 24(1): 53-60.
  10. Zuetenhorst JM, Bonfrer JMG, Korse CM, Bakker R, van Tinteren H, Taal BG. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003; 97(7): 1609-15.
  11. Van Ruth S, Hart AA, Bonfrer JMG, Verwaal VJ, Zoetmulder FA. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9(10): 961-7.
  12. Stieber P, Molina R, Chan DW, Fritsche JA, Beyrau R, Bonfrer JMG, Filella X, Gornet TG, Hoff T, Jager W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I. Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay. Clin Chem 2001; 47(12): 2162-4. No abstract available.
  13. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JMG, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2001; 88(5): 828-32.